Neuren Pharmaceuticals trading halt request

Neuren Pharmaceuticals Limited (ASX: $NEU) has requested a trading halt for its securities. The halt is pending the analysis of data and an announcement related to the top line results of its Phase 2 clinical trial in Pitt Hopkins syndrome. The trading halt will remain in place until the company releases the announcement or until the commencement of trading on Monday, 27 May 2024, whichever is earlier.

Neuren Pharmaceuticals trading halt commentary

The Directors of Neuren Pharmaceuticals Limited have requested the trading halt in accordance with Listing Rule 17.1. The reason for the request is pending an analysis of data and an announcement by the Company in relation to the top line results of its Phase 2 clinical trial in Pitt Hopkins syndrome. The company confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt.

Neuren Pharmaceuticals trading halt summary

Neuren Pharmaceuticals Limited has requested a trading halt pending the announcement of the top line results of its Phase 2 clinical trial in Pitt Hopkins syndrome. The company aims to provide the market with essential information related to the trial. The trading halt will be in place until the announcement is released or until the commencement of trading on Monday, 27 May 2024. This request aligns with the company's commitment to transparent and timely communication with the market regarding significant developments.